Transarterial Chemoembolization (TACE): A Precision…

What is Transarterial Chemoembolization (TACE)?

Transarterial chemoembolization (TACE) is a minimally invasive procedure used to treat primary or metastatic liver tumors. It involves the selective delivery of chemotherapy drugs directly into the hepatic artery, which supplies blood to the tumor, followed by embolization with particles that block blood flow and enhance drug retention within the tumor.

The process aims to deliver high concentrations of chemotherapy agents to the tumor while minimizing systemic side effects, making it a valuable treatment option for patients who are not candidates for surgical resection or other therapies.

How Does TACE Work?

During TACE, an interventional radiologist threads a catheter through the femoral artery and guides it to the hepatic artery using fluoroscopy. The procedure typically involves two main steps: drug delivery and embolization. First, chemotherapy drugs are injected directly into the tumor's blood supply, ensuring high local concentrations. Next, particles such as polyvinyl alcohol (PVA) or gelatin sponges are introduced to occlude the artery, cutting off blood flow to the tumor and preventing further nutrient supply.

This dual approach not only delivers potent chemotherapy but also physically isolates the tumor from normal tissue, enhancing its effectiveness while minimizing systemic toxicity.

live demo · related simulation● LIVE

Why is TACE Important?

TACE is crucial for treating liver tumors that are too large or numerous to be removed surgically. It can also serve as a palliative treatment to alleviate symptoms and improve quality of life in patients with advanced disease. By selectively targeting the tumor, TACE minimizes damage to surrounding healthy tissue, reducing side effects compared to systemic chemotherapy.

Moreover, TACE has been shown to extend survival rates and improve overall outcomes for certain types of liver cancer, making it a vital tool in oncology.

Real-World Applications

TACE is widely used in the treatment of hepatocellular carcinoma (HCC), which accounts for about 80% of primary liver cancers. It can also be employed for metastatic colorectal cancer to the liver, where it has demonstrated significant efficacy. The procedure is particularly effective when combined with other treatments like radiofrequency ablation or surgical resection.

TACE's precision and effectiveness make it a cornerstone in interventional radiology, offering hope to patients facing challenging liver tumors.

Frequently asked questions

What are the risks associated with TACE?

Risks include complications such as infection, bleeding, organ damage, and embolization of non-target vessels. However, these risks are generally low when performed by experienced interventional radiologists.

How long does a typical TACE procedure take?

The duration can vary but typically ranges from 1 to 4 hours, depending on the complexity of the case and the extent of tumor involvement.

Is TACE suitable for all types of liver tumors?

TACE is most effective for certain types of primary and metastatic liver tumors. It may not be appropriate for smaller tumors or those located in areas that are difficult to access via the hepatic artery.

How do doctors decide if TACE is the right treatment option?

Doctors consider factors such as tumor size, location, patient’s overall health, and previous treatments. Imaging studies like CT scans or MRI help in assessing the feasibility of TACE based on tumor characteristics.

Try it live

Everything above runs in your browser — open Transarterial Chemoembolization (TACE) Simulator and change the parameters while it is running. Nothing is installed, nothing is uploaded, the whole model lives in one tab.

▶ Open Transarterial Chemoembolization (TACE) Simulator simulation

Transarterial Chemoembolization (TACE): A Precision Treatment for Liver Tumors